30 Jan, 2024 09:57 AM
-- Arovella has entered into a global, exclusive license with University of North CarolinaLineberger Comprehensive Cancer Center to incorporate a novel armouring cytokinetechnology (IL-12-TM) for it...read more
20 Nov, 2023 01:12 PM
Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased to announce that it has received its FY202...read more
27 Oct, 2023 12:42 PM
MELBOURNE, AUSTRALIA 27 October 2023: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform for cancer treat...read more
12 Oct, 2023 09:29 AM
Arovella has entered into a global, exclusive license with Sparx Group to develop a world-first iNKT cell therapy targeting a validated target, Claudin 18.2 (CLDN18.2), which is...read more
24 Jul, 2023 12:17 PM
MELBOURNE, AUSTRALIA 24 July 2023: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform for cancer tre...read more
11 Jul, 2023 08:54 AM
Highlights:
Arovella completes oversubscribed share purchase plan to raise $2.2 million.
MELBOURNE, AUSTRALIA 11 July 2023: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company...read more
29 Jun, 2023 09:11 AM
Highlights:
SPP Closing Date extended by one week to 5.00pm (AEST) Thursday, 6 July 2023
MELBOURNE, AUSTRALIA 29 June 2023: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focus...read more